DBC1, a novel native inhibitor of anti-aging protein SIRT1
View Patent ↗A novel complex is identified between the NAD-dependent deacetylase, SIRT1 and its novel inhibitor, DBC1. Provided herein are methods to identify a compound that inhibits the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to inhibit the complexation between SIRT1 and DBC1. Also, provided are methods to identify a compound that increases the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to increase the complexation between SIRT1 and DBC1. Further, methods are provided to increase or decrease SIRT1 activity by contacting the complexation between SIRT1 and DBC1 with a peptide that either decreases or increases the complexation between SIRT1 and DBC1. Further, methods are provided for the treatment of patients suffering from diseases including metabolic diseases including obesity and diabetes, and neurodegenerative disorders including Alzheimer's disease and Huntington's disease using compounds that inhibit the complexation between SIRT1 and DBC1.
1. A method for identifying an agent which inhibits the complexation between DBC1 and SIRT1 comprising:
(a) providing a first composition comprising an amount of DBC1 bound to SIRT1 and a control composition comprising the same amount of DBC1 bound to SIRT1 as the first composition;
(b) contacting the first composition with a test agent;
(c) determining i) the level of unbound SIRT in the first composition and the control composition or ii) the level of complexation between SIRT1 and DBC1 in the first composition and the control composition; and
(d) determining i) the difference in the level of unbound SIRT1 in the first composition compared to the control composition or ii) the difference in the level of complexation between SIRT1 and DBC1 in the first composition compared to the control composition;
wherein, if i) the level of unbound SIRT1 in the first composition is higher than the level of unbound SIRT1 in the control composition or ii) the level of complexation between SIRT1 and DBC1 in the first composition is lower than the level of complexation between SIRT1 and DBC1 in the control composition, then the test agent inhibits the complexation between SIRT1 and DBC1.
2. The method of claim 1 , wherein step (b) is performed in vitro.
3. The method of claim 1 , wherein the test agent is a peptide.
4. The method of claim 3 , wherein the peptide can hybridize with DBC1 or SIRT1 under stringent conditions.
5. The method of claim 2 , wherein the difference in the level of unbound SIRT1 or the difference in the level of complexation between SIRT1 and DBC1 is determined by differential centrifugation, chromatography, gel filtration chromatography, ion-exchange chromatography, electrophoresis, immunoprecipitation, pulldown assay, ELISA assays fluorescence energy transfer, surface plasmon resonance, or in vitro tubulin deacetylation assays.
6. The method of claim 1 , wherein step (b) is performed on a cell.
7. The method of claim 1 , wherein step (b) is performed inside a cell.
8. The method of claim 6 , wherein step (b) is performed outside a cell and the test agent causes a cascade effect.
9. The method of claim 6 , wherein the cell is a yeast cell.
10. The method of claim 6 , wherein the cell is a human osteosarcoma U2OS cell.
11. The method of claim 6 , wherein difference in the level of unbound SIRT1 or difference in the level of complexation between SIRT1 and DBC1 is determined by yeast two hybrid, adipoctye differentiation assay, or deacetylation assay.